IV 
117TH CONGRESS 
1ST SESSION 
H. RES. 589 
Expressing the sense of the House of Representatives that policies governing 
access to medication abortion care in the United States should be equi-
table and based on science. 
IN THE HOUSE OF REPRESENTATIVES 
AUGUST 17, 2021 
Mrs. CAROLYN B. MALONEY of New York (for herself, Ms. DEGETTE, Ms. 
LEE of California, Ms. PRESSLEY, Mr. NADLER, Mr. DANNY K. DAVIS 
of Illinois, Ms. SPEIER, Ms. JACOBS of California, Ms. NORTON, Mr. 
CICILLINE, Mr. RASKIN, Ms. SCHAKOWSKY, Mr. WELCH, Mr. TRONE, 
Mr. FOSTER, Ms. MCCOLLUM, Mrs. TORRES of California, Ms. STRICK-
LAND, Ms. CHU, Mr. CONNOLLY, Ms. MANNING, Ms. WASSERMAN 
SCHULTZ, Mr. JOHNSON of Georgia, Ms. BONAMICI, Ms. TITUS, Mr. 
KHANNA, Mr. VARGAS, Mr. GRIJALVA, Mr. BROWN, Ms. MOORE of Wis-
consin, Ms. LOIS FRANKEL of Florida, Mr. POCAN, Mr. AUCHINCLOSS, 
Mr. DESAULNIER, Mr. TORRES of New York, Mr. ESPAILLAT, Ms. 
JAYAPAL, Ms. BROWNLEY, Ms. DELBENE, Ms. VELA´ZQUEZ, Mr. 
QUIGLEY, Mrs. FLETCHER, Mr. LIEU, Ms. DEAN, Mr. COOPER, Ms. 
TLAIB, Ms. CASTOR of Florida, Mr. BLUMENAUER, Mr. JONES, Mr. 
SMITH of Washington, Ms. WILSON of Florida, Ms. CLARKE of New 
York, Ms. WILLIAMS of Georgia, Miss RICE of New York, Ms. GARCIA 
of Texas, Ms. DELAURO, Mr. SARBANES, Mrs. LAWRENCE, Ms. JACKSON 
LEE, Ms. OMAR, Mr. SCHIFF, Mr. EVANS, Mr. KILMER, Mr. TONKO, Ms. 
KELLY of Illinois, Ms. SCHRIER, Mr. VEASEY, Ms. ADAMS, Mrs. WATSON 
COLEMAN, Mrs. NAPOLITANO, Mr. HUFFMAN, Mr. DEFAZIO, Mr. BOW-
MAN, Ms. BASS, Ms. MENG, and Ms. BUSH) submitted the following reso-
lution; which was referred to the Committee on Energy and Commerce 
RESOLUTION 
Expressing the sense of the House of Representatives that 
policies governing access to medication abortion care in 
VerDate Sep 11 2014 
23:37 Aug 17, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\HR589.IH
HR589
kjohnson on DSK79L0C42PROD with BILLS
•HRES 589 IH 
Whereas the REMS restrictions for mifepristone are also op-
posed by the American Medical Association, the American 
Academy of Family Physicians, and other leading medical 
authorities; 
Whereas the World Health Organization recognizes that 
medication abortion plays a crucial role in the provision 
of access to safe, effective abortion care; 
Whereas lifting the in-person dispensing requirement and 
other REMS restrictions for mifepristone would improve 
access without weakening the strong safety profile of the 
drug; 
Whereas patients should be able to receive medication abor-
tion in the way that makes most sense for them from the 
provider of their choosing, whether that is at a health 
center, their local pharmacy, or delivered to their home; 
Whereas unnecessary restrictions on abortion, including medi-
cation abortion, disproportionately push care out of reach 
for people of color, people with lower incomes, those in 
rural communities, and other pregnant people who have 
been disproportionately harmed by burdensome and medi-
cally unnecessary State and Federal restrictions on abor-
tion care, as well as systemic inequities in health care 
that have been exacerbated by the coronavirus pandemic; 
Whereas Congress required that any REMS not be ‘‘unduly 
burdensome on patient access to the drug, considering in 
particular . . . patients who have difficulty accessing 
health care (such as patients in rural or medically under-
served areas)’’, among other factors (section 505– 
1(f)(2)(C)(ii) of the Federal Food, Drug, and Cosmetic 
Act (42 U.S.C. 355–1(f)(2)(C)(ii))); 
VerDate Sep 11 2014 
23:37 Aug 17, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR589.IH
HR589
kjohnson on DSK79L0C42PROD with BILLS
•HRES 589 IH 
Whereas, on April 12, 2021, the FDA announced that it 
would exercise enforcement discretion to temporarily lift 
the in-person dispensing requirement for mifepristone for 
the duration of the coronavirus public health emergency; 
and 
Whereas, on May 7, 2021, the FDA indicated that it is con-
ducting an evidence-based review of the REMS restric-
tions for mifepristone: Now, therefore, be it 
Resolved, That it is the sense of the House of Rep-
resentatives that policies governing access to medication 
abortion care in the United States should— 
(1) be grounded in science and based on a sci-
entific review of available medical evidence; and 
(2) ensure equitable access for patients harmed 
by restrictions that— 
(A) have impeded access to sexual and re-
productive health care; and 
(B) have worsened health disparities for 
people of color, immigrants, people with lower 
incomes, and people in other marginalized com-
munities. 
Æ 
VerDate Sep 11 2014 
23:37 Aug 17, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR589.IH
HR589
kjohnson on DSK79L0C42PROD with BILLS